Previous 10 | Next 10 |
home / stock / mrvl:cc / mrvl:cc news
Calgary, Alberta--(Newsfile Corp. - January 8, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), is pleased to announce a collaboration with Professor Emmanuel Planel o...
Calgary, Alberta--(Newsfile Corp. - November 16, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), is pleased to announce a collaboration with Dr. Julie Le Merrer and Dr. Jerome B...
Calgary, Alberta--(Newsfile Corp. - August 22, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), is pleased to announce that it has successfully completed its 4-week good ...
Calgary, Alberta--(Newsfile Corp. - July 10, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), is pleased to announce that it has been selected to present the Company's scientific advanc...
Calgary, Alberta--(Newsfile Corp. - April 20, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), is pleased to announce that it has completed the dosing portion of the 4-week good l...
Calgary, Alberta--(Newsfile Corp. - March 21, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), is pleased to announce that it has initiated the 4-week good laboratory practice (GLP) FDA...
Calgary, Alberta--(Newsfile Corp. - March 9, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), is pleased to announce that it has initiated the 4-week good laboratory practice (GLP) FDA ...
Calgary, Alberta--(Newsfile Corp. - February 24, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) (" Marvel " or the " Corporation ") announced today that it has completed the closing of the first tranche of the previously announced non-brokered private placement of debentures (" Debentures ") for...
Calgary, Alberta--(Newsfile Corp. - February 15, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) (" Marvel " or the " Company ") announced today its intention to complete a non-brokered private placement offering of unsecured convertible debentures (" Debentures ") in the principal amount of up t...
Calgary, Alberta--(Newsfile Corp. - January 6, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), are pleased to announce that it has successfully completed a multi-kilogram scale run u...
News, Short Squeeze, Breakout and More Instantly...
Marvel Biosciences Corp. Company Name:
MRVL:CC Stock Symbol:
TSXVC Market:
Marvel Biosciences Corp. Website:
Calgary, Alberta--(Newsfile Corp. - July 24, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today is pleased to announce the extension of its collaboration with Drs. Julie Le Me...
Calgary, Alberta--(Newsfile Corp. - July 19, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), is pleased to report that, further to its press releases of May 16, 2024 and June 21, 2024, it has ...
Calgary, Alberta--(Newsfile Corp. - July 9, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to highlight the recently published paper "Neuronal A2A receptor exacerbate...